Patricia Stephenson

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations

Medicine, Oncology, Pharmacology +17

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Suzanne George, Jean‐Yves Blay, Paolo G. Casali et al. · European Journal of Cancer · 2009 · 368 citations

Medicine, Oncology, Pharmacology +13

Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196

Joseph A. Sparano, Patricia Bernardo, Patricia Stephenson et al. · Journal of Clinical Oncology · 2004 · 268 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC).

D. Ross Camidge, Sai‐Hong Ignatius Ou, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2014 · 256 citations

Medicine, Oncology, Pharmacology +13